688428 (688428) News
Follow 688428 (688428) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
InnoCare Pharma Reports 88% Revenue Growth and RMB 648.3M Profit
Revenue for the first three quarters of 2026 rose 88% year over year to RMB 2.1 billion. Net profit was RMB 648.3 million, versus a RMB 72.0 million loss a year earlier; drug sales rose 41.5% to RMB 1.4 billion.
EARNINGS | Oct 26, 2026, 10:44 AM UTC
L
Eli Lilly, InnoCare Sign Deal That Could Top $3 Billion
By Fabiana Negrin OchoaChina-based biopharmaceutical company InnoCare Pharma has signed a research and license agreement with Eli Lilly that could be valued at more than $3 billion.InnoCare, a specialist in cancer and au
NEWS | Sep 24, 2026, 04:54 AM UTC
L
InnoCare Pharma Signs Lilly R&D, Upfronts Up To $100M, Milestones Up To $3.25B
InnoCare Pharma entered a research collaboration and license deal with Eli Lilly, with up to $100M in upfront/near-term payments and up to ~$3.25B in milestones, plus single-digit tiered royalties.Material DetailsContext
NEWS | Sep 24, 2026, 04:23 AM UTC
L
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company ha
NEWS | Sep 24, 2026, 04:22 AM UTC
L
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
Chinese drugmaker InnoCare Pharma SSE:688428 said on Thursday it entered into a research collaboration and license agreement with Eli Lilly NYSE:LLY that could be worth up to about $3.35 billion.
GEOPOLITICS | Sep 24, 2026, 04:19 AM UTC